肉豆蔻酰-DL-维生素BT氯化 | 14919-38-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 肉豆蔻酰-DL-维生素BT氯化
• 中文别名: 3-羧基-N,N,N-三甲基-2-(十四碳酰氧基)-1-丙基氯化铵
• 英文名称: myristoylcarnitine chloride
• 英文别名: 3-Tetradecanoyloxy-4-(trimethylazaniumyl)butanoate;hydrochloride；3-tetradecanoyloxy-4-(trimethylazaniumyl)butanoate;hydrochloride
• CAS: 14919-38-1
• 化学式: C₂₁H₄₂NO₄*Cl
• 分子量: 408.022
• InChiKey: TWGWHMYOGIGWDM-UHFFFAOYSA-N

物化性质

• 溶解度：
  <10.2mg/ml，水中

计算性质

• 辛醇/水分配系数(LogP)：
  1.78
• 重原子数：
  27
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S36/37
• 危险类别码：
  R22

文献信息

• [EN] TOPICAL SLIMMING PREPARATION AND A COSMETIC CONTAINING A CARNITINE DERIVATIVE<br/>[FR] PRÉPARATION EXTERNE POUR L'AMINCISSEMENT DE LA PEAU ET PRODUIT COSMÉTIQUE CONTENANT CETTE PRÉPARATION
  申请人：SHOWA DENKO KK

  公开号：WO2005115326A1

  公开（公告）日：2005-12-08

  The invention provides a slimming skin external preparation and a cosmetic that contain a carnitine derivative having excellent skin affinity and percutaneous absorption properties and capable of enhancing the fat metabolism, and that can treat, reduce or prevent the obesity by functioning as a lipolytic agent to enhance the fat metabolism of general or local subcutaneous fat tissues. The slimming skin external preparation contains a particular carnitine derivative such as a cylcarnitines and alcohol carnitine esters and preferably other slimming and skin-care ingredients.

  本发明提供了一种减肥皮肤外用制剂和化妆品，其中包含一种肉碱衍生物，具有优异的皮肤亲和性和经皮吸收性能，能够增强脂肪代谢，并且能够作为脂肪分解剂，促进一般或局部皮下脂肪组织的脂肪代谢，从而治疗、减少或预防肥胖。该减肥皮肤外用制剂包含特定的肉碱衍生物，如环肉碱和醇肉碱酯，并且最好还包含其他减肥和护肤成分。
• Slimming Skin External Preparation and Cosmetic Containing the Same
  申请人：Shibuya Akira

  公开号：US20070232698A1

  公开（公告）日：2007-10-04

  The invention provides a slimming skin external preparation and a cosmetic that contain a carnitine derivative having excellent skin affinity and percutaneous absorption properties and capable of enhancing the fat metabolism, and that can treat, reduce or prevent the obesity by functioning as a lipolytic agent to enhance the fat metabolism of general or local subcutaneous fat tissues. The slimming skin external preparation contains a particular carnitine derivative and preferably other slimming and skin-care ingredients.

  该发明提供了一种含有卡尼汀衍生物的减肥皮肤外用制剂和化妆品，该衍生物具有优异的皮肤亲和性和经皮吸收性能，并能够增强脂肪代谢，通过作为脂肪分解剂增强一般或局部皮下脂肪组织的脂肪代谢，从而能够治疗、减少或预防肥胖。该减肥皮肤外用制剂含有特定的卡尼汀衍生物，最好还包含其他减肥和护肤成分。
• Pharmaceutical formulations for the oral delivery of peptide or protein drugs
  申请人：Cyprumed GmbH

  公开号：EP3006045A1

  公开（公告）日：2016-04-13

  The present invention relates to improved pharmaceutical formulations, uses and methods for the oral delivery of peptide or protein drugs with advantageously high bioavailability, safety and cost-effectiveness. In particular, the invention provides a peptide or protein drug having a molecular weight of equal to or less than about 50 kDa for use as a medicament, wherein said peptide or protein drug is to be administered orally in combination with a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex, and with a pharmaceutically acceptable reducing agent. The invention also provides a pharmaceutical composition comprising: a peptide or protein drug having a molecular weight of equal to or less than about 50 kDa; a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex; and a pharmaceutically acceptable reducing agent.

  本发明涉及肽或蛋白质药物口服给药的改进药物制剂、用途和方法，具有生物利用度高、安全性好和成本效益高等优点。特别是，本发明提供了一种分子量等于或小于约 50 kDa 的多肽或蛋白质药物，可用作药物，其中所述多肽或蛋白质药物将与药学上可接受的铜盐/络合物和/或药学上可接受的锌盐/络合物以及药学上可接受的还原剂一起口服给药。本发明还提供了一种药物组合物，其中包括：分子量等于或小于约 50 kDa 的多肽或蛋白药物；药学上可接受的铜盐/络合物和/或药学上可接受的锌盐/络合物；以及药学上可接受的还原剂。
• Pharmaceutical formulations for the oral delivery of peptide drugs
  申请人：Cyprumed GmbH

  公开号：US10905744B2

  公开（公告）日：2021-02-02

  The present invention relates to improved pharmaceutical formulations, uses and methods for the oral delivery of peptide drugs with advantageously high bioavailability, safety and costeffectiveness. In particular, the invention provides a peptide drug having a molecular weight of equal to or less than 5 kDa for use as a medicament, wherein said peptide drug is to be administered orally in combination with a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex and/or a pharmaceutically acceptable iron salt/complex, and with a pharmaceutically acceptable complexing agent. The invention also provides a pharmaceutical composition comprising: a peptide drug having a molecular weight of equal to or less than 5 kDa; a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex and/or a pharmaceutically acceptable iron salt/complex; and a pharmaceutically acceptable complexing agent.

  本发明涉及肽类药物口服给药的改进药物制剂、用途和方法，具有生物利用度高、安全和成本效益高等优点。特别是，本发明提供了一种分子量等于或小于 5 kDa 的多肽药物，可用作药物，其中所述多肽药物将与药学上可接受的铜盐/络合物和/或药学上可接受的锌盐/络合物和/或药学上可接受的铁盐/络合物以及药学上可接受的络合剂一起口服给药。本发明还提供了一种药物组合物，其中包括：分子量等于或小于 5 kDa 的多肽药物；药学上可接受的铜盐/络合物和/或药学上可接受的锌盐/络合物和/或药学上可接受的铁盐/络合物；以及药学上可接受的络合剂。
• Pharmaceutical compositions for delivery of peptide
  申请人：ANYA BIOPHARM INC.

  公开号：US11389474B2

  公开（公告）日：2022-07-19

  The present invention relates to a pharmaceutical composition including: a pharmaceutically effective amount of at least one peptide; and a pharmaceutically acceptable amount of a combination of: (a) at least one metal in form of any or a combination of a salt thereof and a complex thereof; and (b) at least one reducing agent, wherein, the at least one metal is selected from any or a combination of: vanadium, chromium and manganese, and wherein the combination of (a) at least one metal in form of any or a combination of a salt and a complex and (b) at least one reducing agent affords protection, at least in part, to the at least one peptide from proteolytic degradation upon ingestion thereof.

  本发明涉及一种药物组合物，包括：药学上有效量的至少一种肽；和药学上可接受量的以下物质的组合：(其中，至少一种金属选自钒、铬和锰中的任意一种或其组合，且(a)至少一种盐和络合物中的任意一种或其组合形式的金属和(b)至少一种还原剂的组合至少部分保护至少一种肽在摄入后不被蛋白水解降解。